Primary central nervous system lymphoma
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
This Primer summarizes the epidemiology, pathophysiology, diagnosis and treatment of primary central nervous system lymphoma. This Primer also reviews future research avenues and the effect that this disorder has on the quality of life of patients. Primary central nervous system lymphoma (PCNSL) is a diffuse large B cell lymphoma in which the brain, spinal cord, leptomeninges and/or eyes are exclusive sites of disease. Pathophysiology is incompletely understood, although a central role seems to comprise immunoglobulins binding to self-proteins expressed in the central nervous system (CNS) and alterations of genes involved in B cell receptor, Toll-like receptor and NF-κB signalling. Other factors such as T cells, macrophages or microglia, endothelial cells, chemokines, and interleukins, probably also have important roles. Clinical presentation varies depending on the involved regions of the CNS. Standard of care includes methotrexate-based polychemotherapy followed by age-tailored thiotepa-based conditioned autologous stem cell transplantation and, in patients unsuitable for such treatment, consolidation with whole-brain radiotherapy or single-drug maintenance. Personalized treatment, primary radiotherapy and only supportive care should be considered in unfit, frail patients. Despite available treatments, 15–25% of patients do not respond to chemotherapy and 25–50% relapse after initial response. Relapse rates are higher in older patients, although the prognosis of patients experiencing relapse is poor independent of age. Further research is needed to identify diagnostic biomarkers, treatments with higher efficacy and less neurotoxicity, strategies to improve the penetration of drugs into the CNS, and roles of other therapies such as immunotherapies and adoptive cell therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Chapuy, B., Stewart, C., Dunford, A. J., Kim, J., Kamburov, A., Redd, R. A., Lawrence, M. S., Roemer, M. G. M., Li, A. J., Ziepert, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0016-8 · Cited by 1,941
Nayak, L., Iwamoto, F. M., LaCasce, A., Mukundan, S., Roemer, M. G. M., Chapuy, B., Armand, P., Rodig, S. J., & Shipp, M. A. (2017) · Blood · doi:10.1182/blood-2017-01-764209 · Cited by 453
Self-citationMontesinos-Rongen, M., Van Roost, D., Schaller, C., Wiestler, O. D., & Deckert, M. (2004) · Blood · doi:10.1182/blood-2003-05-1465 · Cited by 178
Baraniskin, A., Kuhnhenn, J., Schlegel, U., Schmiegel, W., Hahn, S., & Schroers, R. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0908-2 · Cited by 75
Metadata
- Authors
- Ferreri, A. J. M., Calimeri, T., Cwynarski, K., Dietrich, J., Grommes, C., Hoang-Xuan, K., Hu, L. S., Illerhaus, G., Nayak, L., Ponzoni, M., & Batchelor, T. T.
- Venue
- Nature Reviews Disease Primers
- Published
- 2023-06-15
- Volume
- 9
- Issue
- 1
- Pages
- 29-29
- ISSN
- 2056-676X (ISSN-L)
- OpenAlex
- W4380790188
- Cited by
- 252
- References
- 5
- FWCI
- 11.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Primary central nervous system lymphoma. https://app.cochat.ai/papers/10.1038/s41572-023-00439-0
- The paper
- Ferreri, A. J. M., Calimeri, T., Cwynarski, K., Dietrich, J., Grommes, C., Hoang-Xuan, K., Hu, L. S., Illerhaus, G., Nayak, L., Ponzoni, M., & Batchelor, T. T. (2023). Primary central nervous system lymphoma. Nature Reviews Disease Primers. https://doi.org/10.1038/s41572-023-00439-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.